Clinical Trials Logo

Clinical Trial Summary

Primary Objective The primary objective of the study is to assess whether transnasal sphenopalatine ganglion block using the device TX360 reduces intensity and severity of the Post-Traumatic Headache in adolescents. Secondary Objectives The study will also evaluate: - Quality of life (QoL) - Intensity of the headache - Physical function - Sleep quality - Role function (measured by PEDMIDAS) - Adverse events


Clinical Trial Description

The sphenopalatine ganglion (SPG) is a large network of neurons that is easily accessible through the middle turbinate. The SPG is composed of branches from V1 and V2 of the trigeminal nerve and interconnects with sympathetic and parasympathetic autonomic fibers.6 The SPG has been successfully targeted transnasally to treat headache disorders and associated autonomic symptoms in adults.7 SPG blockade has been used in adults for treating several headache and facial pain conditions such as migraine, cluster headache, and trigeminal neuralgia.8 To our knowledge, there has not been any similar study done in children and adolescents. The Tx360® device (Tian Medical Inc., Lombard, IL, USA) allows for noninvasive blockade of the SPG using a small catheter below the middle turbinate of the nose that is administered just beyond the pterygopalatine fossa. Regarding the efficacity of Tx360®, recent studies show that repetitive SPG blockade using 0.5% bupivacaine delivered with the Tx360® device was well-tolerated and effective at decreasing baseline headache intensity in adults.6 ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05213065
Study type Interventional
Source McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact Marie Vigouroux
Phone 5144124448
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date February 5, 2022
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04369729 - Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache
Completed NCT03588364 - The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine N/A
Recruiting NCT05378074 - Hypersensitivity to Opening of BKCa Channels in Post-Traumatic Headache N/A
Recruiting NCT05328635 - Post-traumatic Headache Multidisciplinary Study
Recruiting NCT04776304 - Art Therapy qEEG Study for Service Members With a Traumatic Brain Injury and Posttraumatic Stress Symptoms N/A
Recruiting NCT04614922 - Acceptance and Commitment Therapy-based Rehabilitation of Post-concussion Symptoms N/A
Completed NCT03674398 - Aerobic Exercise and Cognitive Training Effects on Postconcussive Symptomology N/A
Recruiting NCT02965027 - Prazosin for Post-Concussive Headaches Phase 4
Recruiting NCT04906603 - Theta Burst Stimulation for Headaches After Traumatic Brain Injury N/A
Terminated NCT01053507 - Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction Phase 4
Completed NCT02419131 - Cognitive-Behavior Therapy for Posttraumatic Headache N/A
Recruiting NCT03806985 - Effects of Psilocybin in Concussion Headache Phase 1
Completed NCT05243953 - Hypersensitivity to Opening of ATP-Sensitive Potassium Channels in Post-Traumatic Headache N/A
Completed NCT03056352 - Metoclopramide for Post-Traumatic Headache. A Pilot Study Phase 1/Phase 2
Completed NCT01854385 - Sumatriptan as Treatment for Post-traumatic Headache Phase 2
Active, not recruiting NCT03523923 - TBI Care: Collaborative Care for Pain After Traumatic Brain Injury (TBI) N/A
Recruiting NCT05378061 - Hypersensitivity to PACAP-38 in Post-Traumatic Headache N/A
Completed NCT03791515 - Clinical Characteristics and Pathophysiology of Post-Traumatic Headache N/A
Recruiting NCT00219869 - Galantamine in the Treatment of Post-Traumatic Headache Phase 4
Recruiting NCT05093556 - Interactive CBT for Headache And Relaxation Training N/A